Can Neil Woodford reignite the U.K.'s taste for biotech investments?
27 February 2015
High-profile investment guru Neil Woodford has rolled out his $300 million investment vehicle in the U.K., looking to attract a host of small investors behind a publicly traded trust that has big plans for investing in a new wave of small biotechs.
Creating a Culture of Trust & Breakthrough Innovation in Pharma
27 February 2015
Today’s pharma industry is suffering a crisis of trust. To thrive in this new environment, top leaders will not only have to develop innovative patient-centered models, they will also need to achieve enterprise-wide culture change and facilitate breakthrough innovation.
Top 10 drug brands by payments to doctors
26 February 2015
The criticism was inevitable when the U.S. government rolled out its first batch of Sunshine Act data in October. Drugmakers and doctors had already been grousing about omitted entries and misleading info. We at FiercePharma had our own selfish complaint: The Open Payments database is monstrous--way too large for us to download and analyze with our paltry computing power.
Personalized Medicine: The Future of Health Care is Here Today
26 February 2015
Precision medicine has been capturing the headlines big time in the past couple of weeks with major initiatives being created in the U.S. and the UK. Their objective is to marshal resources to be able to accelerate the discovery and delivery of targeted therapies to patients more effectively.
Report lays out vision for enhancing postmarket monitoring of medical devices
26 February 2015
The Brookings Institute laid out its vision of a comprehensive medical device postmarket surveillance system in a report to various device industry stakeholders. The report's ideas were further detailed and debated during a series of moderated discussions at the think tank featuring the CEOs of Medtronic ($MDT) and Edwards Lifesciences ($EW), and the head of FDA's device arm, CDRH.
The 10 largest med tech M&A deals announced in 2014
26 February 2015
The summer of med tech (and pharma) merger mania certainly broadened our lexicon. It also transformed the medical device industry.
Epic Sciences Appoints Chris Bernard as Chief Commercial Officer
25 February 2015
Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a senior executive and company officer leading sales and marketing teams to build biopharma and translational research partnerships and commercialize IVD platforms.
The healthcare system and medical device market in Russia
25 February 2015
This TforG report helps businesses gain a unique insight into the socio-economic dynamics in Russia until 2015, and helps analyze how they affect healthcare systems and their evolution. It can serve as an essential tool for sales, marketing, R&D and business managers with industry related interests.
Data Snapshot: Dwarfed By Big Pharma, Biotech By The Numbers
25 February 2015
Biotech fills the news these days – whether it’s the announcement of exciting new clinical data, another high-flying IPO, or a big M&A deal. Amidst the significant “share of voice” in the coverage of young and emerging biotech in the media, it’s easy to forget the relative scale of the sector relative to larger BioPharma companies.
Venture capital flowing, but BIO study points to fewer start-ups
25 February 2015
The Biotechnology Industry Organization's (BIO) first-ever venture capital study, which analyzed U.S. venture investments during a 10-year period – 2004 to 2013 – turned up several positive trends such as the increasing shift toward biologics and novel drug development, but there was one set of data that gave investors pause. (
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024